U.S. Markets open in 3 hrs 8 mins

GlaxoSmithKline Slumps: GSK Falls 5.9% in Session

Zacks Equity Research

GlaxoSmithKline plc (GSK) saw a big move last session, as the company’s shares fell by about 6% on the day. The move came on pretty good volume too with far more shares changing hands than in a normal session. This continues the recent downtrend for GSK, as the stock is now down 8% since July 10. 

This slump shouldn’t be too much of a surprise to investors, as the healthcare company has seen 2 negative revisions in the past few weeks and its current year earnings consensus has moved lower over the last 30 days. This suggests there may be more trouble down the road. So make sure to keep an eye on this stock going forward to see if this recent slump will continue, as the earnings picture definitely suggests that this might be the case.

GSK currently has a Zacks Rank #5 (Strong Sell).

Some better-ranked stocks in the Large Cap Pharma industry include Allergan Inc. (AGN), Abbott Laboratories (ABT), and AbbVie Inc. (ABBV). While Allergan sports a Zacks Rank #1 (Strong Buy), Abbott and AbbVie hold a Zacks Rank #2 (Buy).  

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 DaysClick to get this free report >>


GLAXOSMITHKLINE PLC (GSK): Free Stock Analysis Report

ALLERGAN INC (AGN): Free Stock Analysis Report

ABBOTT LABS (ABT): Free Stock Analysis Report

ABBVIE INC (ABBV): Free Stock Analysis Report

Zacks Investment Research